Trial reportJournal of magnetic resonance imaging : JMRI2015
Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters.
Trial report in Journal of magnetic resonance imaging : JMRI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Biparametric magnetic resonance imaging assessment for detection of muscle-invasive bladder cancer: a systematic review and meta-analysis.European radiology · 2022Pooled it
- Magnetic Resonance Imaging Sequences and Technologies in Adaptive Radiation Therapy.International journal of radiation oncology, biology, physics · 2025Review
- Diagnostic accuracy and inter-reader agreement of the nacVI-RADS for bladder cancer treated with neoadjuvant chemotherapy: a prospective validation study.European radiology · 2025Article
- Comparative diagnostic performance of VI-RADS based on biparametric and multiparametric MRI in predicting muscle invasion in bladder cancer.BMC medical imaging · 2025Article
- Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer.Insights into imaging · 2025Article
- Retrospective analysis of multiparametric MRI in predicting complete pathologic response of neo-adjuvant chemotherapy in bladder cancer.BMC medical imaging · 2024Article
- Article
- Clinical application of bladder MRI and the Vesical Imaging-Reporting and Data System.Nature reviews. Urology · 2024Review
- Differential performance of imaging modalities predicting pathological response to neoadjuvant chemotherapy in urothelial bladder cancer: a systematic review and meta-analysis.Central European journal of urology · 2024Review
- Review
- Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors.International journal of molecular sciences · 2022Review
- MR-Guided Adaptive Radiotherapy for Bladder Cancer.Frontiers in oncology · 2021Review
- [The role of the vesical imaging-reporting and data system (VI-RADS) for bladder cancer diagnostics-status quo].Der Urologe. Ausg. A · 2019Review
- Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).European urology · 2018Review
- A glance at imaging bladder cancer.Clinical and translational imaging · 2018Article
- Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy?Bladder cancer (Amsterdam, Netherlands) · 2017Article
- Advances in Imaging in Prostate and Bladder Cancer.Current urology reports · 2017Review
- Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study.European radiology · 2017Article
- Preoperative Imaging for Clinical Staging Prior to Radical Cystectomy.Current urology reports · 2016Review
- Performance of simultaneous high temporal resolution quantitative perfusion imaging of bladder tumors and conventional multi-phase urography using a novel free-breathing continuously acquired radial compressed-sensing MRI sequence.Magnetic resonance imaging · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo apply k-means clustering of two pharmacokinetic parameters derived from 3T dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict the chemotherapeutic response in bladder cancer at the mid-cycle timepoint. MATERIALS AND
methodsWith the predetermined number of three clusters, k-means clustering was performed on nondimensionalized Amp and kep estimates of each bladder tumor. Three cluster volume fractions (VFs) were calculated for each tumor at baseline and mid-cycle. The changes of three cluster VFs from baseline to mid-cycle were correlated with the tumor's chemotherapeutic response. Receiver-operating-characteristics curve analysis was used to evaluate the performance of each cluster VF change as a biomarker of chemotherapeutic response in bladder cancer.
resultsThe k-means clustering partitioned each bladder tumor into cluster 1 (low kep and low Amp), cluster 2 (low kep and high Amp), cluster 3 (high kep and low Amp). The changes of all three cluster VFs were found to be associated with bladder tumor response to chemotherapy. The VF change of cluster 2 presented with the highest area-under-the-curve value (0.96) and the highest sensitivity/specificity/accuracy (96%/100%/97%) with a selected cutoff value.
conclusionThe k-means clustering of the two DCE-MRI pharmacokinetic parameters can characterize the complex microcirculatory changes within a bladder tumor to enable early prediction of the tumor's chemotherapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.